...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
【24h】

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research

机译：迈向针对恶性疟疾的基于RTS，S的多阶段，多抗原疫苗：沃尔特·里德陆军研究所的研究进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The goal of the Malaria Vaccine Program at the Walter Reed Army Institute of Research (WRAIR) is to develop a licensed multi-antigen, multi-stage vaccine against Plasmodium falciparum able to prevent all symptomatic manifestations of malaria by preventing parasitemia. A secondary goal is to limit disease in vaccinees that do develop malaria. Malaria prevention will be achieved by inducing humoral and cellular immunity against the pre-erythrocytic circumsporozoite protein (CSP) and the liver stage antigen-1 (LSA-1). The strategy to limit disease will target immune responses against one or more blood stage antigens, merozoite surface protein-1 (MSP-1) and apical merozoite antigen-1 (AMA-1). The induction of T- and B-cell memory to achieve a sustained vaccine response may additionally require immunization with an adenovirus vector such as adenovirus serotype 35. RTS,S, a CSP-derived antigen developed by GlaxoSmithKline Biologicals in collaboration with the Walter Reed Army Institute of Research over the past 17 years, is the cornerstone of our program. RTS,S formulated in AS02A (a GSK proprietary formulation) is the only vaccine candidate shown in field trials to prevent malaria and, in one instance, to limit disease severity. Our vaccine development plan requires proof of an individual antigen's efficacy in a Phase 2 laboratory challenge or field trial prior to its integration into an RTS,S-based, multi-antigen vaccine. Progress has been accelerated through extensive partnerships with industrial, academic, governmental, and non-governmental organizations. Recent safety, immunogenicity, and efficacy trials in the US and Africa are presented, as well as plans for the development of a multi-antigen vaccine.
机译：沃尔特·里德陆军研究所（WRAIR）的疟疾疫苗计划的目标是开发一种针对恶性疟原虫的许可多抗原，多阶段疫苗，该疫苗能够通过预防寄生虫病来预防疟疾的所有症状表现。次要目标是限制确实患有疟疾的疫苗中的疾病。预防疟疾将通过诱导针对红细胞前环子孢子蛋白（CSP）和肝阶段抗原1（LSA-1）的体液和细胞免疫来实现。限制疾病的策略将针对一种或多种血液阶段抗原，裂殖子表面蛋白-1（MSP-1）和根部裂殖子抗原-1（AMA-1）的免疫反应。诱导T细胞和B细胞记忆以实现持续的疫苗反应可能还需要使用腺病毒载体（例如35型腺病毒）进行免疫。RTS，S是葛兰素史克（GlaxoSmithKline Biologicals）与沃尔特·里德陆军（Walter Reed Army）合作开发的CSP衍生抗原在过去的17年中，研究所是我们计划的基石。 AS02A（GSK专有配方）中配制的RTS，S是现场试验中显示的唯一可预防疟疾并在某种情况下限制疾病严重性的候选疫苗。我们的疫苗开发计划要求在将其整合到基于RTS，S的多抗原疫苗之前，要在2期实验室挑战或现场试验中证明单个抗原的功效。通过与工业，学术，政府和非政府组织建立广泛的伙伴关系，加速了进步。介绍了在美国和非洲进行的近期安全性，免疫原性和功效试验，以及开发多抗原疫苗的计划。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号